Atara Biotherapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.793 million. Revenue was USD 0.957 million compared to USD 51.58 million a year ago. Net loss was USD 71.11 million compared to net income of USD 18.47 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to basic earnings per share from continuing operations of USD 0.18 a year ago. Diluted loss per share from continuing operations was USD 0.68 compared to diluted earnings per share from continuing operations of USD 0.18 a year ago.
For the six months, sales was USD 1.68 million. Revenue was USD 2.18 million compared to USD 58.89 million a year ago. Net loss was USD 145.88 million compared to USD 69.64 million a year ago. Basic loss per share from continuing operations was USD 1.4 compared to USD 0.69 a year ago. Diluted loss per share from continuing operations was USD 1.4 compared to USD 0.69 a year ago.